KDM2B and diffuse large B-cell lymphoma: Thus, these findings provide insights into how the dysregulation of a chromatin modifier is coupled to sustaining proliferative kinase signaling pathway in DLBCL and also reveal the clinical importance of FBXL10 in DLBCL.